Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Novartis
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Hoffmann-La Roche
Columbia University
Eisai Inc.
Massachusetts Eye and Ear Infirmary
Olivia Newton-John Cancer Research Institute
Assistance Publique - Hôpitaux de Paris
Hoffmann-La Roche
Corcept Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Advanced Accelerator Applications
Alliance for Clinical Trials in Oncology
Jonsson Comprehensive Cancer Center
Elidah, Inc.
National Cancer Center, Korea
Dana-Farber Cancer Institute
Advanced Accelerator Applications
University of Washington
Imperial College London
Azienda Ospedaliera Universitaria Integrata Verona
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Technische Universität Dresden
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Murdoch Childrens Research Institute
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University Health Network, Toronto
St. Jude Children's Research Hospital
Novartis
Changi General Hospital
Washington University School of Medicine
National Cancer Institute (NCI)
Colorado State University